Urgent Recall Issued for Hair Growth Serum Over Child Safety Concerns
Health officials in the United States have issued an urgent recall for thousands of bottles of a popular hair serum, warning that the products pose a risk of serious injury or death to young children. The recall affects 27,400 spray bottles of Tomum Hair Regrowth Treatment with Minoxidil for Men and Women, which were sold through Amazon between March 2025 and September 2025.
Critical Packaging Failure Identified
The US Consumer Product Safety Commission (CPSC) announced the recall on Thursday, stating that the bottles do not have child-resistant packaging. This violation directly contravenes the Poison Prevention Packaging Act of 1970, which mandates that products containing minoxidil—a hair growth medication—must feature such packaging. The requirement exists because ingesting even small amounts of minoxidil can cause extreme drops in blood pressure and dangerous increases in heart rate.
The CPSC explicitly warned: "The hair serum’s bottles are not child-resistant, posing a risk of serious injury or death from poisoning if the contents are swallowed by young children." To date, no injuries or adverse effects related to this specific recall have been reported.
Product Details and Consumer Instructions
The affected products were distributed by Belleka Inc of China and sold in 100mL bottles for approximately $20 each. The spray bottles are silver with a blue wraparound label and a black cap, packaged in a blue box. Both the bottle and box display "TOMUM" and "Hair Growth Treatment" on their front labels.
Consumers are urged to take immediate action:
- Secure the recalled serum bottles out of sight and reach of children immediately.
- Contact Belleka for a free replacement product, which includes two child-resistant bottles of serum (60 mL per unit).
- Dispose of the recalled product bottle and send a photo of the bottle in the trash to Belleka at tomumcs@gmail.com.
For questions, consumers can email Belleka, call 862-244-1785, or contact the company through its official website.
Broader Context of Minoxidil Safety and Market Trends
Minoxidil has surged in popularity in recent years, alongside other hair loss treatments like finasteride. Approximately 13 million Americans were estimated to use minoxidil in 2024, contributing to a booming US hair loss market. Industry projections suggest this market will more than double in value, from $2.8 billion to over $5.3 billion within the next decade.
The medication works by enhancing blood flow to hair follicles, stimulating regrowth and restoring hair in bald patches. When formulated in low concentrations for topical use, it is generally safe, minimizing risks to patients. However, if ingested, medical treatment typically involves administering large fluids and medications to stabilize blood pressure.
It is important to note that the FDA has only approved minoxidil as a drug for treating hair loss, and it is also marketed under the brand name Rogaine in the US.
Recent Similar Recalls Highlight Ongoing Concerns
This recall is not an isolated incident. Several other hair products containing minoxidil have been recalled recently for identical packaging failures:
- In August 2025, Sefralls Minoxidil Hair Generation Serum, sold in amber dropper bottles for $10 on Amazon, was recalled due to lack of child-resistant packaging. No injuries or deaths have been reported.
- Last July, a recall was issued for Aemerry Hair Growth Serums, which also were not sold in child-safe bottles.
Despite these recalls, there are no publicly reported fatalities in the US to date among young children who accidentally consumed minoxidil. Nevertheless, the CPSC emphasizes that the potential for severe harm remains significant, warranting strict adherence to safety protocols and prompt consumer response to recall notices.
